Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Zirabev [legacy through FY23] by Quarter
Zirabev (bevacizumab biosimilar) [legacy through FY23] — U.S. reported YoY (%) (%)
Pfizer Zirabev [legacy through FY23]: -31.0% in Q4 2023, down 44.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
“|| Zirabev | 88 | 130 | (32%) | (32%) | 66 | 97 | (31%) | 22 | 33 | (34%) | (32%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zirabev (bevacizumab biosimilar) [legacy through FY23] — U.S. reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | -31.0% | -44.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| Q3 2023 | Oct 1, 2023 | -41.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗ |
| Q2 2023 | Jul 2, 2023 | -25.0% | -60.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗ |
| Q1 2023 | Apr 2, 2023 | -8.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 13.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| Q2 2022 | Jul 3, 2022 | 35.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-07032022xex99.htm, filed 2022-07-28) ↗ |
Cite this data
StockData. (2026). Pfizer Zirabev [legacy through FY23] (%), quarterly Q2 2022–Q4 2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/zirabev-leg-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.